ClinicalTrials.Veeva

Menu

HYPNOsis in the Management of Atopic Dermatitis in Children and Teenagers (HypnoDA)

C

Centre Hospitalier Universitaire de la Réunion

Status

Enrolling

Conditions

Dermatitis

Treatments

Behavioral: Hypnosis

Study type

Interventional

Funder types

Other

Identifiers

NCT05611346
2022/CHU/15

Details and patient eligibility

About

Atopic dermatitis (AD) is a chronic inflammatory dermatosis, common in children. It causes pruritus and skin lesions that can have a significant impact on patients' quality of life. AD can be difficult to treat because of its chronicity, demanding local care, corticophobia and the financial cost of non-reimbursed products. Patients are often looking for therapeutic alternatives. Medical hypnosis is a therapeutic alternative via hypnoanalgesia induced by direct suggestions of comfort and skin soothing and via anxiolysis, by working on stress management and self-esteem reinforcement. Four studies are interested in its action in AD and seem to show a reduction in pruritus, skin pain, an improvement in the intensity of atopic dermatitis, sleep, mood and for some a cure of AD. These results are encouraging but limited by the absence of a control group or by the small population included. Therefore, we propose in a first step to evaluate the feasibility of an hypnosis program through a pilot study, designed in the miniature format of a future, larger scale, randomized controlled trial.

Enrollment

32 estimated patients

Sex

All

Ages

8 to 17 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Children aged 8 to 17 years
  • Understanding french
  • Have a clinical diagnosis of mild-to-severe AD with a SCORing Atopic Dermatitis (SCORAD)
  • Referred by their referring physician in the Reunionese therapeutic education program for AD provided within the atopy school of the Reunion University Hospital. - Oral consent of the child and of one of the legal representatives collected.

Exclusion criteria

  • Children refusing to participate in the hypnosis session
  • Not having the possibility to listen to an audio file,
  • Already practicing self-hypnosis for their AD before inclusion,
  • Having a contraindication to hypnosis (psychiatric disorders, psychosis)
  • Treated by a systemic treatment for their AD.

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

32 participants in 2 patient groups

Therapeutic education program
No Intervention group
Therapeutic education program and Hypnosis
Experimental group
Treatment:
Behavioral: Hypnosis

Trial contacts and locations

1

Loading...

Central trial contact

Juliette MIQUEL, MD; Camille ESPAGNON, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems